Visikol

Biotech company focused on transforming tissues in 3D insights to accelerate drug discovery and improve the diagnosis of disease.

Visikol, Inc., is focused on accelerating drug discovery through the 3D digitization of biological tissues and mining these large data sets for actionable insights. The company has developed a patented tissue clearing technology called Visikol HISTO that when paired with fluorescent labeling and 3-D microscopy allows tissues such as 3-D cell culture models or whole tissues to be imaged in their entirety in 3-D. Visikol has leveraged this technology to launch 3Screen which is a high-throughput 3-D imaging platform capable of transforming tissues into 3D data sets and answering complex biological questions. The addition of 3-D histological information to the drug discovery workflow allows for complex features such as vasculature networks to be quantitatively analyzed in 3-D or for the penetration kinetics of antibodies into tumor models to be understood. The company currently offers 3Screen as a service to pharmaceutical/biotech companies and is continually focused on improving the platform as well as building out a suite of standardized assays. In addition to this service offering, Visikol also sells various tissue clearing reagents and kits for academic researchers that are interested in adopting the approach into their own workflows.